CDKN2B-AS1 and cancer: The lncRNA ANRIL is up-regulated in a variety of malignant tumors, acting as a novel oncogene in tumorigenesis and progression, promoting tumor cell proliferation, apoptosis, and metastasis, and reducing survival [19, 22, 23, 29, 30].